ArticleCancer medicine2026
Serum Bile Acid Metabolomics-Based Machine Learning Model for Non-Invasive Diagnosis of Gastric Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGastric cancer (GC) has posed a severe threat to human health. Metabolomics analysis has been applied in the context of multiple diseases, offering new perspectives for the development of non-invasive detections.
objectiveWe aimed to develop a diagnostic model for GC based on a serum bile acid (BA) panel.
methodsA total of 632 participants were recruited for serum samples collection, and their clinical characteristics were recorded. Targeted BA profiling was conducted using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). Participants from Xi'an were randomly allocated into a training cohort and an internal tuning cohort at a 7:3 ratio. The key BAs were identified through the two-step selection method, and nine machine learning (ML) models were constructed and optimized. The optimal model was further evaluated externally using an independent validation cohort from Lanzhou.
resultsA panel of 10 serum BAs was confirmed for the construction of a diagnostic model. The XGBoost model exhibited the best performance on the tuning cohort, with an area under the receiver operating characteristic curve (AUROC) of 0.858. It also exhibited robust performance on the external validation cohort (AUROC = 0.816), significantly outperforming tumor markers (with the highest AUROC of CA72-4 = 0.68). The developed model also demonstrated satisfactory predictive performance for patients with resectable stage GC (Stage I-II) (average precision [AP] = 0.75).
conclusionGC patients exhibit BA metabolic disorders. The XGBoost model based on a 10-BA panel exhibited superior efficacy in GC detection, indicating its promising potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.